Tonghua Dongbao Pharmaceutical Dirección

Dirección controles de criterios 3/4

El CEO de Tonghua Dongbao Pharmaceutical's es Sheng Leng Chun, nombrado en May 2020, tiene una permanencia de 3.92 años. posee directamente un 0.11% de las acciones de la empresa, con un valor de CN¥23.65M. La antigüedad media del equipo directivo y de la junta directiva es de 3.9 años y 3.9 años, respectivamente.

Información clave

Sheng Leng Chun

Chief Executive Officer (CEO)

CN¥3.7m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	4.1yrs
Participación del CEO	0.1%
Permanencia media de la dirección	4.1yrs
Promedio de permanencia en la Junta Directiva	4.1yrs

Actualizaciones recientes de la dirección

Recent updates

Improved Earnings Required Before Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) Shares Find Their Feet

May 23

CEO

Sheng Leng Chun (50 yo)

4.1yrs

Permanencia

CN¥3,728,800

Compensación

Mr. Chun Sheng Leng serves as a Director and General Manager since Mach 27, 2024 and served as the Chairman and General Manager at Tonghua Dongbao Pharmaceutical Co., Ltd. since May 7, 2020 until March 27,...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Sheng Leng Chun	GM & Director	4.1yrs	CN¥3.73m	0.12% CN¥ 20.6m
Junyu Chi	Chief Accountant	4.1yrs	CN¥852.40k	sin datos
Hong Chen	Chief Engineer & Deputy GM	10.3yrs	CN¥527.20k	0.015% CN¥ 2.6m
Guodong Zhang	Deputy GM & Director	4.1yrs	CN¥1.17m	0.013% CN¥ 2.4m
Wenhai Zhang	Deputy GM & Director	4.1yrs	CN¥1.17m	0.030% CN¥ 5.4m
Zhiqiang Du	Deputy General Manager	2.6yrs	CN¥1.45m	sin datos
Fan Su	Deputy GM & Board Secretary	4yrs	CN¥992.50k	sin datos

4.1yrs

Permanencia media

50yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 600867 se considera experimentado (3.9 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Sheng Leng Chun	GM & Director	10.3yrs	CN¥3.73m	0.12% CN¥ 20.6m
Guodong Zhang	Deputy GM & Director	4.1yrs	CN¥1.17m	0.013% CN¥ 2.4m
Wenhai Zhang	Deputy GM & Director	4.1yrs	CN¥1.17m	0.030% CN¥ 5.4m
Junye Wang	Chairman of the Supervisory Board	3.8yrs	CN¥1.17m	0.12% CN¥ 20.8m
Fu Bo Cao	Supervisor	4.1yrs	CN¥173.20k	sin datos
Wei Wang	Director	3.8yrs	sin datos	sin datos
Qingxia He	Employee Representative Supervisor	4.1yrs	sin datos	sin datos
Jiahong Li	Chairman of the Board	4.1yrs	CN¥173.20k	sin datos
Yan Bi	Independent Director	8.9yrs	CN¥100.00k	sin datos
Dai Xu	Independent Director	2.1yrs	CN¥100.00k	sin datos
Li Xu	Independent Director	2.1yrs	CN¥100.00k	sin datos
Jianchun Zhen	Director	less than a year	sin datos	sin datos

4.1yrs

Permanencia media

50yo

Promedio de edad

Junta con experiencia: La junta directiva de 600867 se considera experimentada (3.9 años de antigüedad promedio).

Tonghua Dongbao Pharmaceutical Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Tonghua Dongbao Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Price target decreased by 8.4% to CN¥13.15

Improved Earnings Required Before Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) Shares Find Their Feet

Consensus EPS estimates increase by 14%

Consensus EPS estimates fall by 16%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Tonghua Dongbao Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

Investor sentiment improves as stock rises 16%

Full year 2023 earnings released: EPS: CN¥0.59 (vs CN¥0.79 in FY 2022)

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 08, 2024

Price target increased by 7.4% to CN¥14.25

Price target increased by 8.2% to CN¥13.75

Adocia Announces its Partner Tonghua Dongbao Releases Positive Results on the Three Clinical Studies Conducted on BioChaperone Combo THDB0207 Formulation Containing Insulin Glargine and Insulin Lispro from Tonghua Dongbao

Consensus EPS estimates fall by 10%, revenue upgraded

Second quarter 2023 earnings: EPS misses analyst expectations

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 22, 2023

Price target increased by 14% to CN¥12.83

Full year 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improves as stock rises 16%

Full year 2022 earnings released: EPS: CN¥0.80 (vs CN¥0.64 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to CN¥11.27

Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) commences an Equity Buyback for CNY 360 million worth of its shares, under the authorization approved on March 25, 2022.

Consensus forecasts updated

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates increase by 15%

Less than half of directors are independent

Full year 2021 earnings: EPS exceeds analyst expectations

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Full year 2021 earnings: EPS exceeds analyst expectations

An unknown buyer signed an agreement to acquire 5% stake in Xiamen Amoytop Biotech Co., Ltd. (SHSE:688278) from Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) for CNY 460 million.

Tonghua Dongbao Pharmaceutical Co., Ltd.(XSSC:600867) dropped from FTSE All-World Index (USD)

Third quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.10 in 3Q 2020)

Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) commences an Equity Buyback Plan for 24,000,000 shares, representing 1.18% for CNY 360 million, under the authorization approved on August 25, 2021.

Price target decreased to CN¥13.56

Second quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.13 in 2Q 2020)

Full year 2020 earnings released: EPS CN¥0.46 (vs CN¥0.40 in FY 2019)

Price target decreased to CN¥14.96

New 90-day low: CN¥11.82

Full year 2020 earnings released: EPS CN¥0.46

Revenue behind estimates

New 90-day low: CN¥12.87

New 90-day low: CN¥13.32

New 90-day high: CN¥14.91

Third quarter earnings released

Third-quarter earnings released: Revenue and earnings miss expectations

Earnings released

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 20, 2020

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad